ATE466014T1 - Spiroazacyclische verbindungen als monoaminrezeptormodulatoren - Google Patents

Spiroazacyclische verbindungen als monoaminrezeptormodulatoren

Info

Publication number
ATE466014T1
ATE466014T1 AT02797503T AT02797503T ATE466014T1 AT E466014 T1 ATE466014 T1 AT E466014T1 AT 02797503 T AT02797503 T AT 02797503T AT 02797503 T AT02797503 T AT 02797503T AT E466014 T1 ATE466014 T1 AT E466014T1
Authority
AT
Austria
Prior art keywords
compounds
monoamine receptor
receptor modulators
methods
spiroazacyclic compounds
Prior art date
Application number
AT02797503T
Other languages
English (en)
Inventor
Nathalie Schlienger
Original Assignee
Acadia Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acadia Pharm Inc filed Critical Acadia Pharm Inc
Application granted granted Critical
Publication of ATE466014T1 publication Critical patent/ATE466014T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Photoreceptors In Electrophotography (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT02797503T 2001-12-28 2002-12-23 Spiroazacyclische verbindungen als monoaminrezeptormodulatoren ATE466014T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34475001P 2001-12-28 2001-12-28
PCT/US2002/041476 WO2003057698A2 (en) 2001-12-28 2002-12-23 Spiroazacyclic compounds as monoamine receptor modulators

Publications (1)

Publication Number Publication Date
ATE466014T1 true ATE466014T1 (de) 2010-05-15

Family

ID=23351865

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02797503T ATE466014T1 (de) 2001-12-28 2002-12-23 Spiroazacyclische verbindungen als monoaminrezeptormodulatoren

Country Status (16)

Country Link
US (6) US6911452B2 (de)
EP (1) EP1461339B1 (de)
JP (1) JP4535728B2 (de)
KR (2) KR100974901B1 (de)
CN (2) CN101050215A (de)
AT (1) ATE466014T1 (de)
AU (1) AU2009213086A1 (de)
BR (1) BR0215429A (de)
CA (1) CA2470575C (de)
DE (1) DE60236206D1 (de)
MX (1) MXPA04006280A (de)
NO (1) NO20042964L (de)
NZ (2) NZ571695A (de)
RU (2) RU2315051C2 (de)
WO (1) WO2003057698A2 (de)
ZA (1) ZA200405028B (de)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2002126554A (ru) * 2000-03-06 2004-03-20 Акадиа Фармасьютикалз, Инк. (Us) Азациклические соединения для применения при лечении опосредованных серотонином заболеваний
WO2003057698A2 (en) 2001-12-28 2003-07-17 Acadia Pharmaceuticals, Inc. Spiroazacyclic compounds as monoamine receptor modulators
US7253186B2 (en) 2002-06-24 2007-08-07 Carl-Magnus Andersson N-substituted piperidine derivatives as serotonin receptor agents
CN100509804C (zh) 2002-06-24 2009-07-08 阿卡蒂亚药品公司 N-取代哌啶衍生物作为血清素受体试剂
US7538222B2 (en) * 2002-06-24 2009-05-26 Acadia Pharmaceuticals, Inc. N-substituted piperidine derivatives as serotonin receptor agents
MY139563A (en) * 2002-09-04 2009-10-30 Bristol Myers Squibb Co Heterocyclic aromatic compounds useful as growth hormone secretagogues
PT1587789E (pt) 2003-01-16 2008-12-16 Acadia Pharm Inc Agonistas inversos selectivos para receptores 2a/2c da serotonina como agentes terapêuticos para doenças neurodegenerativas
WO2004092169A1 (ja) * 2003-04-18 2004-10-28 Ono Pharmaceutical Co., Ltd. スピロピペリジン化合物およびその医薬用途
EP1786815B1 (de) * 2003-09-10 2011-08-24 Virochem Pharma Inc. Spiroverbindungen und -verfahren zur modulation von chemokin-rezeptor-aktivität
JPWO2005047286A1 (ja) * 2003-11-13 2007-05-31 小野薬品工業株式会社 スピロ複素環化合物
PL1691811T3 (pl) 2003-12-11 2014-12-31 Sunovion Pharmaceuticals Inc Skojarzenie leku uspokajającego i modulatora neuroprzekaźnikowego oraz sposoby poprawy jakości snu i leczenia depresji
RU2006132465A (ru) 2004-02-10 2008-03-20 Ф.Хоффманн-Ля Рош Аг (Ch) Модуляторы хемокинового рецептора ccr5
US7820695B2 (en) * 2004-05-21 2010-10-26 Acadia Pharmaceuticals, Inc. Selective serotonin receptor inverse agonists as therapeutics for disease
US20050261278A1 (en) 2004-05-21 2005-11-24 Weiner David M Selective serotonin receptor inverse agonists as therapeutics for disease
EP1604980A1 (de) * 2004-06-08 2005-12-14 Santhera Pharmaceuticals (Deutschland) Aktiengesellschaft DPP-IV-Hemmer
EP1790639B1 (de) 2004-08-27 2014-03-26 Ono Pharmaceutical Co., Ltd. Spirocyclische verbindungen und ihre verwendung als cxcr4-antagonisten
US7790899B2 (en) 2004-09-27 2010-09-07 Acadia Pharmaceuticals, Inc. Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms
JP4996467B2 (ja) 2004-09-27 2012-08-08 アカディア ファーマシューティカルズ インコーポレイテッド Ｎ−（４−フルオロベンジル）−ｎ−（１−メチルピペリジン−４−イル）−ｎ’−（４−（２−メチルプロピルオキシ）フェニルメチル）カルバミド、並びにその酒石酸塩及び結晶形態の合成
US8114887B2 (en) 2004-10-13 2012-02-14 Merck, Sharp & Dohme Corp. Spiropiperidine compounds useful as beta-secretase inhibitors for the treatment of alzheimer's disease
ES2547724T3 (es) * 2004-11-10 2015-10-08 Incyte Corporation Compuestos de lactama y su uso como productos farmacéuticos
US8110581B2 (en) 2004-11-10 2012-02-07 Incyte Corporation Lactam compounds and their use as pharmaceuticals
DE602006014531D1 (de) * 2005-03-03 2010-07-08 Janssen Pharmaceutica Nv Substituierte oxadiazaspiro-ä5.5ü-undecanonderivate und ihre verwendung als neurokininantagonisten
NZ556628A (en) 2005-03-08 2009-09-25 Janssen Pharmaceutica Nv Diaza-spiro-[4.4]-nonane derivatives as neurokinin (NK1) antagonists
US7687243B1 (en) * 2005-06-06 2010-03-30 Crook Tonia M Automated method for detecting apoptosis in cells
DE102005030051A1 (de) 2005-06-27 2006-12-28 Grünenthal GmbH Substituierte 1-Oxa-3,8-diazaspiro[4,5]-decan-2-on-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln
JP2009502786A (ja) 2005-07-18 2009-01-29 メルク エンド カムパニー インコーポレーテッド アルツハイマー病を治療するためのスピロピペリジンβ−セクレターゼ阻害剤
EP2258358A3 (de) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenese mit Acetylcholinesterasehemmer
EP2275095A3 (de) 2005-08-26 2011-08-17 Braincells, Inc. Neurogenese durch modulation des Muscarinrezeptors
EP1940389A2 (de) 2005-10-21 2008-07-09 Braincells, Inc. Modulation von neurogenese durch pde-hemmung
AU2006308889A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. GABA receptor mediated modulation of neurogenesis
WO2007058322A1 (ja) 2005-11-18 2007-05-24 Ono Pharmaceutical Co., Ltd. 塩基性基を含有する化合物およびその用途
WO2007065256A1 (en) * 2005-12-06 2007-06-14 Virochem Pharma Inc. Novel spiropiperidine compounds and methods for the modulation of chemokine receptor activity
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
JP2009536667A (ja) 2006-05-09 2009-10-15 ブレインセルス，インコーポレイティド ５ｈｔ受容体介在性の神経新生
EP2382975A3 (de) 2006-05-09 2012-02-29 Braincells, Inc. Neurogenese mittels Angiotensin-Modulation
WO2007132846A1 (ja) 2006-05-16 2007-11-22 Ono Pharmaceutical Co., Ltd. 保護されていてもよい酸性基を含有する化合物およびその用途
US20100298342A1 (en) * 2006-09-07 2010-11-25 Merck & Co., Inc. Spiropiperidine beta-secretase inhibitors for the treatment of Alzheimer's Disease
AU2007292848A1 (en) 2006-09-08 2008-03-13 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
WO2008054698A2 (en) * 2006-10-30 2008-05-08 Merck & Co., Inc. Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease
US7682464B2 (en) * 2006-10-31 2010-03-23 Resurgent Health & Medical, Llc Automated washing system with compliance verification
HRP20130713T1 (en) 2007-03-19 2013-09-30 Acadia Pharmaceuticals Inc. Combinations of 5-ht2a inverse agonists and antagonists with antipsychotics
WO2008119663A1 (en) * 2007-03-29 2008-10-09 F. Hoffmann-La Roche Ag Heterocyclic antiviral compounds
CL2008001839A1 (es) 2007-06-21 2009-01-16 Incyte Holdings Corp Compuestos derivados de 2,7-diazaespirociclos, inhibidores de 11-beta hidroxil esteroide deshidrogenasa tipo 1; composicion farmaceutica que comprende a dichos compuestos; utiles para tratar la obesidad, diabetes, intolerancia a la glucosa, diabetes tipo ii, entre otras enfermedades.
JP2010540454A (ja) * 2007-09-21 2010-12-24 アカディア ファーマシューティカルズ，インコーポレーテッド ピマバンセリンと他の薬剤との併用投与
EP2348857B1 (de) 2008-10-22 2016-02-24 Merck Sharp & Dohme Corp. Neue cyclische benzimidazolderivate als antidiabetika
US8329914B2 (en) 2008-10-31 2012-12-11 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US8389539B2 (en) * 2009-12-01 2013-03-05 Hoffman-La Roche Inc. Azacyclic derivatives
JP2013520502A (ja) 2010-02-25 2013-06-06 メルク・シャープ・エンド・ドーム・コーポレイション 有用な抗糖尿病薬である新規な環状ベンズイミダゾール誘導体
US8097634B2 (en) * 2010-04-15 2012-01-17 Hoffmann-La Roche Inc. Azacyclic derivatives
RU2603263C2 (ru) * 2010-07-13 2016-11-27 Ф. Хоффманн-Ля Рош Аг Новые азациклические соединения
US20120165331A1 (en) * 2010-12-22 2012-06-28 Sangamesh Badiger Di/tri-aza-spiro-C9-C11alkanes
SG192941A1 (en) 2011-02-25 2013-09-30 Merck Sharp & Dohme Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
WO2013052716A1 (en) * 2011-10-07 2013-04-11 Glaxosmithkline Llc Fatty acid synthase inhibitors
WO2014008223A2 (en) * 2012-07-03 2014-01-09 Glaxosmithkline Llc Fatty acid synthase inhibitors
RU2015106909A (ru) 2012-08-02 2016-09-27 Мерк Шарп И Доум Корп. Антидиабетические трициклические соединения
WO2014139388A1 (en) 2013-03-14 2014-09-18 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
TW201615643A (zh) * 2014-06-02 2016-05-01 伊史帝夫博士實驗室股份有限公司 具有多重模式抗疼痛活性之１－氧雜－４，９－二氮雜螺十一烷化合物之烷基與芳基衍生物
PL3325444T3 (pl) 2015-07-20 2021-12-06 Acadia Pharmaceuticals Inc. Sposoby wytwarzania N-(4-fluorobenzylo)-N-(1-metylopiperydyn-4-ylo)-N'-(4-(2-metylopropyloksy)fenylometylo)karbamidu oraz jego soli winianowej i postaci polimorficznej C
US10689398B2 (en) 2015-10-23 2020-06-23 Esteve Pharmaceuticals, S.A. OXA-Diazaspiro compounds having activity against pain
WO2017165635A1 (en) 2016-03-25 2017-09-28 Acadia Pharmaceuticals Inc. Combination of pimavanserin and cytochrome p450 modulators
US10953000B2 (en) 2016-03-25 2021-03-23 Acadia Pharmaceuticals Inc. Combination of pimavanserin and cytochrome P450 modulators
EP3558311A1 (de) 2016-12-20 2019-10-30 Acadia Pharmaceuticals Inc. Pimavanserin allein oder in kombination zur verwendung in der behandlung von morbus-alzheimer-psychose
WO2018200977A1 (en) 2017-04-28 2018-11-01 Acadia Pharmaceuticals Inc. Pimavanserin for treating impulse control disorder
WO2019046167A1 (en) 2017-08-30 2019-03-07 Acadia Pharmaceuticals Inc. PIMAVANSERIN FORMULATIONS
WO2020048827A1 (en) 2018-09-03 2020-03-12 Bayer Aktiengesellschaft 1, 3, 9-triazaspiro[5.5] undecan-2-one compounds
WO2020048826A1 (en) 2018-09-03 2020-03-12 Bayer Aktiengesellschaft 5-substituted 1-oxa-3,9-diazaspiro[5.5]undecan-2-one compounds
CN115605202B (zh) 2020-03-26 2025-10-28 盐野义制药株式会社 具有血清素受体结合活性的芳香族杂环衍生物
CN112169836A (zh) * 2020-09-28 2021-01-05 广东石油化工学院 一种多孔离子聚合物多相催化剂及其催化合成n-甲酰胺的方法
TW202328148A (zh) * 2021-09-22 2023-07-16 日商塩野義製藥股份有限公司 具有血清素受體結合活性之螺雜環衍生物

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE794333A (fr) 1972-01-20 1973-07-19 Wyeth John & Brother Ltd Composes heterocycliques azotes therapeutiques
GB1507462A (en) 1974-03-21 1978-04-12 Gallardo Antonio Sa N-heterocyclic substituted benzamides methods for their preparation and compositions containing them
US3983234A (en) 1974-07-04 1976-09-28 Sandoz Ltd. Treatment of dyskinesias
DE2508188A1 (de) * 1975-02-26 1976-09-09 Kalk Chemische Fabrik Gmbh Bis-(guanidinium)-tetrabromdian und verfahren zu dessen herstellung
GB1586468A (en) 1976-10-29 1981-03-18 Anphar Sa Piperidine derivatives
CA1140119A (en) 1978-04-03 1983-01-25 Joseph Torremans N-heterocyclyl-4-piperidinamines
US4255432A (en) * 1979-09-06 1981-03-10 Syntex (U.S.A.) Inc. 8-[2-3-Indolyl)ethyl]-1-oxa-3-,8-diazaspiro[4.5]decan-2-ones, pharmaceutical compositions thereof and methods of use thereof
US4332804A (en) 1981-03-23 1982-06-01 Syntex (U.S.A.) Inc. 9-[2-(3-Indolyl)ethyl]-1oxa-4,9-diazaspiro[5.5]undecan-3-ones
US4353900A (en) * 1981-10-19 1982-10-12 Syntex (U.S.A.) Inc. 9-(Arylalkyl or aroylalkyl)-1-oxa-4,9-diazaspiro(5.5)undecan-3-ones
US4353901A (en) * 1981-10-19 1982-10-12 Syntex (U.S.A.) Inc. 9-(1,4-Benzodioxan-2-ylalkyl and hydroxyalkyl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-ones
US4863394A (en) * 1985-05-20 1989-09-05 General Electric Company Electrical connector with double torsion contacts
GB8527052D0 (en) * 1985-11-02 1985-12-04 Beecham Group Plc Compounds
GB8621892D0 (en) 1986-09-11 1986-10-15 Lundbeck & Co As H Organic compound
FR2642069B1 (fr) 1989-01-20 1991-04-12 Rhone Poulenc Sante Nouveaux derives du benzopyranne, leur preparation et les compositions pharmaceutiques qui les contiennent
US5534520A (en) * 1990-04-10 1996-07-09 Fisher; Abraham Spiro compounds containing five-membered rings
US5214055A (en) 1990-05-18 1993-05-25 Adir Et Compagnie Aminopiperidine 4-oxo-4H-chromen-2-yl compounds
DE4024415A1 (de) * 1990-08-01 1992-02-06 Hoechst Ag Verfahren zur herstellung von 1-oxa-3,8-diaza-4-oxo-spiro-(4,5)decan- verbindungen
US5216165A (en) 1990-10-03 1993-06-01 American Home Products Corporation N-substituted aminoquinolines as analgesic agents
IT1252227B (it) 1991-12-17 1995-06-05 Ciba Geigy Spa Composti tetrametilpiperidinici atti all'impiego come stabilizzanti per materiali organici
US5595872A (en) 1992-03-06 1997-01-21 Bristol-Myers Squibb Company Nucleic acids encoding microsomal trigyceride transfer protein
CA2123728A1 (en) 1993-05-21 1994-11-22 Noriyoshi Sueda Urea derivatives and their use as acat inhibitors
JPH09501404A (ja) 1993-05-26 1997-02-10 スミスクライン・ビーチャム・ラボラトワール・ファルマソーティク 新規化合物
IL110298A (en) * 1993-07-13 1999-04-11 Brann Mark Robert Identification of ligands by selective amplification of cells transfected with receptors
DE4404183A1 (de) 1994-02-10 1995-08-17 Merck Patent Gmbh 4-Amino-1-piperidylbenzoylguanidine
US5795894A (en) 1995-05-02 1998-08-18 Schering Corporation Piperazino derivatives as neurokinn antagonists
BR9610277A (pt) 1995-08-31 1999-07-06 Schering Corp Derivados de piperazino como antagonistas de neurowuinina
WO1997011940A1 (en) 1995-09-29 1997-04-03 Eli Lilly And Company Spiro compounds as inhibitors of fibrinogen-dependent platelet aggregation
EP0944388A4 (de) 1996-04-03 2001-08-16 Merck & Co Inc Hemmern von farnesyl protein transferase
US5891889A (en) 1996-04-03 1999-04-06 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
EP0960104B1 (de) 1996-04-17 2004-06-16 Bristol-Myers Squibb Pharma Company N-(amidinophenyl)-n'-(subst.)-3h-2,4-benzodiazepin-3-on derivative als faktor xa inhibitoren
US5869488A (en) 1996-05-01 1999-02-09 Schering Corporation Piperazino derivatives as neurokinin antagonists
US5877173A (en) 1996-08-28 1999-03-02 Washington University Preventing neuronal degeneration in Alzheimer's disease
SK285631B6 (sk) 1996-09-10 2007-05-03 Dr. Karl Thomae Gmbh Modifikované aminokyseliny, farmaceutický prostriedok s ich obsahom a ich použitie
DE19643331A1 (de) 1996-10-21 1998-04-23 Thomae Gmbh Dr K 1-(4-Piperidinyl)-piperidinylene, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
US6057338A (en) 1997-04-04 2000-05-02 Merck & Co., Inc. Somatostatin agonists
TR199902752T2 (xx) 1997-05-08 2000-06-21 Smithkline Beecham Corporation Proteaz inhibit�rleri.
US6107324A (en) * 1998-04-14 2000-08-22 Arena Pharmaceuticals Inc. 5-HT2A receptor inverse agonists
US6140509A (en) * 1998-06-26 2000-10-31 Arena Pharmaceuticals, Inc. Non-endogenous, constitutively activated human serotonin receptors and small molecule modulators thereof
US6358698B1 (en) * 1998-10-07 2002-03-19 Acadia Pharmacueticals Inc. Methods of identifying inverse agonists of the serotonin 2A receptor
CA2315050C (en) 1998-10-16 2009-02-03 Suntory Limited Aminophenoxyacetic acid derivatives and pharmaceutical composition containing thereof
US6150393A (en) * 1998-12-18 2000-11-21 Arena Pharmaceuticals, Inc. Small molecule modulators of non-endogenous, constitutively activated human serotonin receptors
EP1013276A1 (de) 1998-12-23 2000-06-28 Pfizer Inc. Aminoazacycloalkane als CCR5-Modulatoren
JP2002539260A (ja) 1999-03-24 2002-11-19 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア アスパルチルプロテアーゼインヒビターを使用して神経変性障害を処置する方法
US6399619B1 (en) 1999-04-06 2002-06-04 Merck & Co., Inc. Pyrrolidine modulators of chemokine receptor activity
DE60023492T2 (de) 1999-05-17 2006-07-20 Novo Nordisk A/S Glucagon antagonisten/inverse agonisten
US20050148018A1 (en) 1999-10-07 2005-07-07 David Weiner Methods of identifying inverse agonists of the serotonin 2A receptor
FR2802206B1 (fr) 1999-12-14 2005-04-22 Sod Conseils Rech Applic Derives de 4-aminopiperidine et leur utilisation en tant que medicament
US7022698B2 (en) 1999-12-28 2006-04-04 U & I Pharmaceuticals, Ltd. Pharmaceutical compositions containing new polymorphic forms of olanzapine and uses thereof
RU2002126554A (ru) 2000-03-06 2004-03-20 Акадиа Фармасьютикалз, Инк. (Us) Азациклические соединения для применения при лечении опосредованных серотонином заболеваний
GB0011838D0 (en) 2000-05-17 2000-07-05 Astrazeneca Ab Chemical compounds
KR100823908B1 (ko) * 2000-10-20 2008-04-21 바이오비트럼 에이비(피유비엘) 2-, 3-, 4-, 또는 5-치환-ｎ1-(벤젠술포닐)인돌 및 이의치료 용도
GB0108099D0 (en) 2001-03-30 2001-05-23 Hoffmann La Roche Aminopiperidine derivatives
BR0209076A (pt) * 2001-04-25 2004-08-10 Altana Pharma Ag Derivados de piperazino e seu uso como inibidor de pde4
DE10150897A1 (de) * 2001-10-18 2003-05-15 Siemens Ag Schlauchklemmeinrichtung
WO2003057698A2 (en) 2001-12-28 2003-07-17 Acadia Pharmaceuticals, Inc. Spiroazacyclic compounds as monoamine receptor modulators
EP1509505A2 (de) 2002-01-23 2005-03-02 Arena Pharmaceuticals, Inc. Nicht-endogene, konstitutiv aktivierte rezeptoren für menschliches serotonin und modulatoren von kleiner molekülgrösse
UY27668A1 (es) 2002-02-20 2003-10-31 Pfizer Prod Inc Composición de ziprasidona y controles sintéticos
GB0208279D0 (en) 2002-04-10 2002-05-22 Glaxo Group Ltd Novel compounds
CN100509804C (zh) 2002-06-24 2009-07-08 阿卡蒂亚药品公司 N-取代哌啶衍生物作为血清素受体试剂
US7253186B2 (en) 2002-06-24 2007-08-07 Carl-Magnus Andersson N-substituted piperidine derivatives as serotonin receptor agents
US7538222B2 (en) 2002-06-24 2009-05-26 Acadia Pharmaceuticals, Inc. N-substituted piperidine derivatives as serotonin receptor agents
WO2004009549A2 (en) 2002-07-18 2004-01-29 Actelion Pharmaceuticals Ltd Piperidines useful for the treatment of central nervous system disorders
AU2003284899A1 (en) 2002-10-29 2004-05-25 Miicro, Inc. Novel combination therapy for schizophrenia focused on improved cognition: 5-ht-2a/d2 blockade with adjunctive blockade of prefrontal da reuptake
PT1587789E (pt) 2003-01-16 2008-12-16 Acadia Pharm Inc Agonistas inversos selectivos para receptores 2a/2c da serotonina como agentes terapêuticos para doenças neurodegenerativas
JP2006515628A (ja) 2003-01-23 2006-06-01 アカディア ファーマシューティカルズ，インコーポレーテッド ヒト神経精神疾患を処置するためのｎ−デスメチルクロザピンの使用
SI1594840T1 (sl) 2003-02-17 2006-12-31 Hoffmann La Roche Derivati piperidin-benzensulfonamida
WO2005002522A2 (en) * 2003-06-30 2005-01-13 Caritas St. Elizabeth's Medical Center Of Boston, Inc. Compositions and methods for treating tissue ischemia
PT1696931E (pt) 2003-12-22 2009-06-12 Acadia Pharm Inc Análogos diaril[a,d]ciclo-hepteno substituídos com amino utilizados como agonistas muscarínicos e métodos de tratamento de perturbações neuropsiquiátricas
US20060288610A1 (en) * 2004-05-14 2006-12-28 Columbia Sportswear North America, Inc. Convertible sandal
US20050261278A1 (en) 2004-05-21 2005-11-24 Weiner David M Selective serotonin receptor inverse agonists as therapeutics for disease
JP4996467B2 (ja) 2004-09-27 2012-08-08 アカディア ファーマシューティカルズ インコーポレイテッド Ｎ−（４−フルオロベンジル）−ｎ−（１−メチルピペリジン−４−イル）−ｎ’−（４−（２−メチルプロピルオキシ）フェニルメチル）カルバミド、並びにその酒石酸塩及び結晶形態の合成
KR100707198B1 (ko) * 2005-06-27 2007-04-13 삼성전자주식회사 나노포어 및 핵산에 비특이적으로 결합하는 물질을 이용한고감도 핵산 검출 방법

Also Published As

Publication number Publication date
AU2002361872A1 (en) 2003-07-24
US20050256108A1 (en) 2005-11-17
CN1612877A (zh) 2005-05-04
EP1461339B1 (de) 2010-04-28
WO2003057698A3 (en) 2003-07-31
NO20042964L (no) 2004-09-07
NZ571695A (en) 2010-02-26
US7511053B2 (en) 2009-03-31
BR0215429A (pt) 2004-12-14
RU2004123210A (ru) 2006-01-20
US20060199794A1 (en) 2006-09-07
KR20100008799A (ko) 2010-01-26
JP2005517682A (ja) 2005-06-16
US7402590B2 (en) 2008-07-22
HK1071890A1 (zh) 2005-08-05
EP1461339A2 (de) 2004-09-29
US7727999B2 (en) 2010-06-01
KR100974901B1 (ko) 2010-08-10
CN101050215A (zh) 2007-10-10
JP4535728B2 (ja) 2010-09-01
MXPA04006280A (es) 2004-09-27
RU2007128351A (ru) 2009-01-27
US20030166928A1 (en) 2003-09-04
US7351707B2 (en) 2008-04-01
US20070161621A1 (en) 2007-07-12
CA2470575C (en) 2011-02-22
US20060205710A1 (en) 2006-09-14
US6911452B2 (en) 2005-06-28
DE60236206D1 (de) 2010-06-10
NZ533567A (en) 2007-06-29
CN100372848C (zh) 2008-03-05
ZA200405028B (en) 2005-08-31
WO2003057698A2 (en) 2003-07-17
AU2009213086A1 (en) 2009-10-08
CA2470575A1 (en) 2003-07-17
AU2002361872B2 (en) 2009-06-11
KR20040077693A (ko) 2004-09-06
US7217719B2 (en) 2007-05-15
RU2315051C2 (ru) 2008-01-20
US20090131418A1 (en) 2009-05-21

Similar Documents

Publication Publication Date Title
ATE466014T1 (de) Spiroazacyclische verbindungen als monoaminrezeptormodulatoren
DK1461318T3 (da) Tetrahydroquinolinanaloge som muscariniske agonister
YU40701A (sh) Piperidini kao modulatori ccr5
TW200634006A (en) Tetrahydroquinoline analogues as muscarinic agonists
YU38801A (sh) Azabicikloalkani kao modulatori ccr5
DE60133029D1 (de) Mittel zur prävention oder behandlung von psoriasi
DE60231341D1 (de) Fluor- und sulfonylaminohaltige, 3,6-disubstituierptorantagonisten
PT1200412E (pt) Agentes anti-proliferativos de imidazole
BRPI0411582A (pt) substáncias terapêuticas contendo boro hidroliticamente resistentes e método de uso
TW200600087A (en) Methods and compositions for treating amyloid-related diseases
UA96115C2 (uk) Спосіб і композиція для лікування амілоїдогенних захворювань
DK0751939T5 (da) Naphthylamider som centralnervesystemmidler
WO2003104425A3 (en) NEW STABLE ANTI-CD22 ANTIBODIES
BR0309278A (pt) Composto, composição, métodos para modular a atividade da cinesina ksp, para inibir a ksp, para o tratamento de uma doença proliferativa celular, e, uso de um composto
DE60033649D1 (de) Verbindungen und therapeutische methoden
CY1109366T1 (el) Υποκατεστημενες ενωσεις 1,4,8-τριαζασπειρο[4.5]δεκαν-2-ονης
TR200200066T2 (tr) Migrenin tedavisi için seçici iGluR5 reseptör antagonistleri
EA200501868A1 (ru) ТРИЦИКЛИЧЕСКИЕ δ-ОПИОИДНЫЕ МОДУЛЯТОРЫ
ATE357917T1 (de) Behandlung von dyskinesie durch mu-selektive opioidantagonisten
PT932613E (pt) Expressao de bloqueio de factoes de virulencia em s. aureus
TNSN05158A1 (fr) Association destinee au traitement de l'adhd
DE69729183D1 (de) Als entzündungshemmende mittel nützliche dihydrobenzofurane und verwandte verbindungen
ATE457027T1 (de) Substituierte 1,4,8-triazaspiroä4.5 decan-2-on- verbindungen zur behandlung von fettsucht
AP2001002188A0 (en) 5HT1 antagonists for antidepressant therapy.
ATE373000T1 (de) Pyrazolopyridin-derivate als antiherpesmittel

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties